51,967 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Tejara Capital Ltd

Tejara Capital Ltd bought a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 51,967 shares of the company’s stock, valued at approximately $381,000.

Other institutional investors have also added to or reduced their stakes in the company. State of Alaska Department of Revenue increased its holdings in shares of Vir Biotechnology by 33.0% in the fourth quarter. State of Alaska Department of Revenue now owns 202,441 shares of the company’s stock valued at $1,485,000 after purchasing an additional 50,199 shares during the last quarter. Charles Schwab Investment Management Inc. increased its holdings in shares of Vir Biotechnology by 13.6% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,134,276 shares of the company’s stock valued at $8,496,000 after purchasing an additional 136,087 shares during the last quarter. State Street Corp increased its holdings in shares of Vir Biotechnology by 10.4% in the third quarter. State Street Corp now owns 5,625,533 shares of the company’s stock valued at $42,135,000 after purchasing an additional 530,645 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of Vir Biotechnology by 0.5% in the fourth quarter. Rhumbline Advisers now owns 236,681 shares of the company’s stock valued at $1,737,000 after purchasing an additional 1,288 shares during the last quarter. Finally, abrdn plc acquired a new position in shares of Vir Biotechnology in the fourth quarter valued at $2,666,000. 65.32% of the stock is currently owned by institutional investors and hedge funds.

Vir Biotechnology Price Performance

Shares of Vir Biotechnology stock opened at $7.01 on Tuesday. The business’s 50 day simple moving average is $9.49 and its two-hundred day simple moving average is $8.42. The stock has a market capitalization of $961.37 million, a P/E ratio of -1.79 and a beta of 1.17. Vir Biotechnology, Inc. has a one year low of $6.56 and a one year high of $14.45.

Vir Biotechnology (NASDAQ:VIR) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.09. The company had revenue of $12.37 million for the quarter, compared to analysts’ expectations of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. Sell-side analysts expect that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Insider Activity at Vir Biotechnology

In other news, EVP Verneuil Vanina De sold 7,373 shares of the company’s stock in a transaction dated Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the sale, the executive vice president now owns 79,460 shares in the company, valued at $726,264.40. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director George A. Scangos sold 10,964 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the transaction, the director now directly owns 708,295 shares of the company’s stock, valued at $6,948,373.95. The trade was a 1.52 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,859 shares of company stock worth $326,458 in the last quarter. 15.60% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have commented on VIR shares. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price objective on shares of Vir Biotechnology in a report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, February 28th. Morgan Stanley raised shares of Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $10.00 to $20.00 in a research report on Thursday, January 9th. Barclays boosted their target price on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research report on Thursday, January 9th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $35.67.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).